23 completed, 6 unknown, 2 recruiting, 1 active not recruiting. 33 Phase 2, 6 Phase 1, 5 Phase 3.
Follow Bordetella Infections: new trials by email Literature Review of Bordetella Infections trials Research Report on Bordetella Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine, Diphtheria, Tetanus and Acellular Component Pertussis Combined Vaccine+Inactivated Poliomyelitis Vaccine Made From Sabin Strains - Diphtheria, Pertussis | Phase 1 / Phase 2 | Recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 380 | 2026-10-11 | 2026-10-23 |
| A Phase II Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents) Tdap vaccine, Placebo - Pertussis (Whooping Cough), Diphtheria | Phase 2 | Recruiting | Changchun BCHT Biotechnology Co. | 420 | 2026-08-12 | 2026-10-26 |
| Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine low-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), high-dose Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content), Tetanus, Diphtheria and Acellular Pertussis Vaccine - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus | Phase 1 / Phase 2 | Not yet recruiting | Institute of Medical Biology, Chinese Academy of Medical Sciences | 660 | 2026-03-12 | 2026-02-18 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp)), 23-valent Pneumococcal Polysaccharide Vaccine (PPV23), Tdcp - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | CanSino Biologics Inc. | 1820 | 2024-12-20 | 2026-08-26 |
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2024-10-02 | 2024-10-01 |
| Pertussis Challenge Study in Adults Vaccinated With BPZE1 BPZE1, Placebo, Azithromycin - Pertussis/Whooping Cough, Bordetella Pertussis, Whooping Cough | Phase 2 | Completed | ILiAD Biotechnologies | 53 | 2022-06-20 | 2025-03-12 |
| Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines Pertagen®, Revaxis® - Pertussis, Vaccine-Preventable Diseases | Phase 2 / Phase 3 | Unknown | University Hospital, Geneva | 100 | 2022-02-07 | 2022-01-18 |
| Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children BPZE1 pertussis vaccine and placebo, BPZE1 pertussis vaccine and Boostrix, Placebo and Boostrix - Bordetella Pertussis, Whooping Cough | Phase 2 | Completed | ILiAD Biotechnologies | 368 | 2021-11-11 | 2025-11-06 |
| Maternal Pertussis Wholecell Responses Standard of care vaccines, Boostagen, (BioNet-Asia) - Pertussis | Phase 2 | Completed | St George's, University of London | 181 | 2020-10-21 | 2023-11-22 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2019-11-01 | 2019-09-06 |
| A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults GC3111 vaccine, Boostrix® vaccine - Tetanus, Diphtheria | Phase 2 | Unknown | Green Cross Corporation | 213 | 2019-10-14 | 2020-01-23 |
| Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device - Pertussis, Whooping Cough | Phase 2 | Completed | ILiAD Biotechnologies | 300 | 2019-06-15 | 2023-06-27 |
| A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine Vaccine GamLPV, Placebo - Whooping Cough | Phase 1 / Phase 2 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 50 | 2019-06-04 | 2019-07-31 |
| Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants Tetanus and Diphtheria Toxoids Adsorbed, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide - Clostridium Difficile Immunisation, Diphtheria | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 399 | 2019-01-24 | 2025-05-21 |
| Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults BPZE1, Placebo - Pertussis, Pertussis Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2018-10-23 | 2024-09-19 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| The PertADO Geneva Trial Pertagen® aP + Td-pur®, Boostrix® dTpa - Pertussis | Phase 2 | Completed | Siegrist Claire-Anne | 60 | 2016-10-27 | 2017-05-08 |
| Maternal Tdap Immunization in Guatemala Tdap, Td - Pertussis, Whooping Cough | Phase 2 | Completed | Emory University | 286 | 2016-07-01 | 2019-10-16 |
| Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine Biological: GC3111 vaccine, Biological: Boostrix® vaccine - Tetanus, Diphtheria | Phase 1 / Phase 2 | Unknown | Green Cross Corporation | 220 | 2016-06-01 | 2016-11-07 |
Showing 20 of 33. Sign in to see all of them.
Whooping Cough (33) · Tetanus (22) · Diphtheria (21) · Hepatitis B (12) · Poliomyelitis (11) · Haemophilus Infections (8) · Gram-Negative Bacterial Infections (1) · Infections (1) · Meningitis, Meningococcal (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Vaccine-Preventable Diseases (1)
Bacterial Infections (33) · Bacterial Infections and Mycoses (33) · Gram-Negative Bacterial Infections (32) · Infections (32) · Respiratory Tract Diseases (32) · Respiratory Tract Infections (32) · Clostridium Infections (22) · Gram-Positive Bacterial Infections (22) · Actinomycetales Infections (21) · Corynebacterium Infections (21) · Virus Diseases (14) · Blood-Borne Infections (12) · Communicable Diseases (12) · DNA Virus Infections (12)
Tetanus Toxoid (8) · Boostrix (4) · Vaccines, Combined (4) · adacel (4) · Diphtheria-Tetanus-acellular Pertussis Vaccines (3) · Poliovirus Vaccine, Inactivated (3) · Hepatitis B Vaccines (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · Azithromycin (1) · Biological Products (1) · DTaP-IPV-HB-PRP-T vaccine (1) · FHD (1) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (1) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (1) · Hiberix (1)
Sanofi Pasteur, a Sanofi Company (5) · GlaxoSmithKline (4) · LG Chem (4) · ILiAD Biotechnologies (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Green Cross Corporation (2) · Institute of Medical Biology, Chinese Academy of Medical Sciences (2) · CanSino Biologics Inc. (1) · Changchun BCHT Biotechnology Co. (1) · Emory University (1) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Sanofi (1) · Scott Halperin (1) · Siegrist Claire-Anne (1)
United States (6) · China (4) · Philippines (4) · Canada (3) · South Korea (3) · Switzerland (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Costa Rica (1) · Guatemala (1) · Japan (1) · Mali (1) · Mexico (1) · Russia (1)
Barbara Rizzardi, MD (1) · Claire-Anne Siegrist, MD (1) · Edison Alberto, MD (1) · Hanqing He (1) · Jiawei Xu (1) · Jose M Ramirez, MD; PhD (1) · Josefina Carlos, MD (1) · Kirsty Le Doare, MBBS, PhD (1) · Manish Sadarangani, MRCPCH, DPHIL, BM.BCh, MA (1) · Marina Rusanova (1) · Mary B Manning, MD (1)
PMID 20657177, PMID 21372751, PMID 23241989, PMID 24346596, PMID 25540274, PMID 30010773, PMID 30759183, PMID 36906345, PMID 38461048, PMID 38586589, PMID 39706666, PMID 41344352, PMID 42822488